National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2015 (No. 1) (PB 3 of 2015) (Cth)

PB 3 of 2015

National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2015 (No. 1)

National Health Act 1953
___________________________________________________________________________

I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.

Dated 24 January 2015

KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch

Pharmaceutical Benefits Division

Department of Health

___________________________________________________________________________

1       Name of Instrument

(1)This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2015 (No.1).

(2)This Instrument may also be cited as PB 3 of 2015.

2              Commencement

This Instrument commences on 1 February 2015.

3              Amendments to PB 116 of 2010

Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).

Schedule 1       Amendments

1. Part 1, Division 1, Section 4 , definition of medication for the treatment of HIV or AIDS

   substitute:

   (a)  abacavir;
      (b)  abacavir with lamivudine;
      (c)  abacavir with lamivudine and zidovudine;
      (d)  atazanavir;
      (e)  azithromycin;
      (f)  clarithromycin;
      (g)  darunavir;
     (h)  didanosine;
     (i)  doxorubicin, pegylated liposomal;
      (j)  efavirenz;
     (k)  emtricitabine;
                        (l)  enfuvirtide;
      (m)  etravirine;
      (n)  fosamprenavir;
      (o)  foscarnet;
      (p)  ganciclovir;
     (q)  indinavir;
     (r)  lamivudine;
     (s)  lamivudine with zidovudine;
      (t)  lopinavir with ritonavir;
      (u)  maraviroc;
                        (v)  nevirapine;
      (w)  raltegravir;
      (x)  rifabutin;
      (y)  rilpivirine
                        (z)  ritonavir;
                        (za)  saquinavir;
                        (zb)  stavudine;
                        (zc)  tenofovir;
                        (zd)  tenofovir with emtricitabine;
                        (ze)  tenofovir with emtricitabine and efavirenz;
                        (zf)  tenofovir with emtricitabine and rilpivirine;
                        (zg)  valaciclovir;
                        (zh)  valganciclovir;
                        (zi)  zidovudine.

2. Schedule 1, entry for Cidofovir

   omit:

Cidofovir Solution for I.V. infusion 375 mg (anhydrous) in 5 mL single use vial Injection Vistide GI EMP C1610 C3322 4 3 D

1. Schedule 3, entry for Cidofovir

   omit:

Cidofovir	C1610	Where the patient is receiving treatment at/from a private hospital Treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome	Compliance with Written or Telephone Authority Required procedures
C3322	Where the patient is receiving treatment at/from a public hospital Treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome	Compliance with Written or Telephone Authority Required procedures ‑ Streamlined Authority Code 3322